Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hours.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Gilead Sciences, Inc. and Novartis Pharmaceuticals Corporation.
Oncology Best Practice™: Integrating Car-T Cell Therapy for the Treatment of Lymphoid Malignancies: What the Community Oncologist Needs to Know
Oncology Best Practice™:
Integrating Car-T Cell Therapy for the Treatment of Lymphoid Malignancies: What the Community Oncologist Needs to Know
In order to request this CME/CE activity for your center, please contact Samantha Zelasko at SZelasko@gotoper.com or call (609) 325-4668
This 1.0 AMA credit program will describe unique aspects of chimeric antigen receptor (CAR) T-cell therapy, including considerations in the timing of patient referrals. Expert faculty will provide updates of key clinical data supporting the use of CAR T cells in patients with relapsed/refractory lymphoid malignancies, including acute lymphoblastic leukemia and aggressive non-Hodgkin lymphoma. Additionally, this program will illustrate the characteristic adverse events associated with CAR T-cell therapy and strategies to manage these toxicities. The activity will utilize a variety of formats, including presentation of new data, clinical scenarios exploring the evidence behind treatment decisions, Q&A sessions to encourage peer-to-peer and peer-to-expert interactions, and the sharing of best practices.
Benefits of Attending
- Gain expert insights into the unique mechanism of action of CAR T cells
- Recognize the importance of early referral for candidates for CAR T-cell therapy
- Evaluate the clinical efficacy and safety of CAR T cells in patients with relapsed/refractory hematologic malignancies
- Learn how to diagnose and manage cytokine release syndrome and neurotoxicity associated with CAR T-cell therapy
This educational activity is directed toward community oncologists and hematologists who treat patients with lymphoid malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lymphoid malignancies will be invited to participate.
- Recognize the unique mechanism of CAR T-cell action and the nuances of manufacture of CAR T-cell therapy
- Evaluate clinical trial data in the context of CAR T-cell therapy and its place in evolving hematologic malignancy treatment paradigms
- Explain pathways for the use of CAR T cells, including identification of eligible patients, process of referral to the treatment centers, and the importance of posttreatment follow-up
- Determine the potential CAR T-cell treatment-related toxicities and best practices for adverse event detection, grading, monitoring, management, and mitigation
Fred Hutch Bone Marrow Transplant Program & Seattle Cancer Care Alliance